Identification of novel NFKB1 and ICOS frameshift variants in patients with CVID
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxac121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Anli Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Common Variable Immunodeficiency. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: State Key Clinical Specialty of China for Hematological Diseases, National Natural Science Foundation of China, Rongxiang Regenerative Medicine Foundation of Shandong University.
Abstract (Originalsprache)
Common variable immunodeficiency (CVID) is a ‘late-onset’ primary immunodeficiency characterized by variable manifestations and genetic heterogeneity. A monogenic cause of CVID has been reported in 10% of patients. In this study, we identified two novel pathogenic variants implicated in monogenic CVID by whole exome sequencing (WES) analysis: a heterozygous nuclear factor κB subunit 1 (NFKB1) p.G686fs mutation and a homozygous inducible T-cell co-stimulator (ICOS) p.L96Sfs mutation. The predicted crystal models indicated premature truncation of the two mutated proteins. Both variants were demonstrated as loss-of-function mutations and were associated with overlapped manifestations of respiratory fungal infection and splenomegaly. We further performed a detailed assessment of immunologic phenotypes and impaired lymphocyte functions in patients. Moreover, we discovered an association between monoclonal T-large granular lymphocyte proliferation and ICOS-deficient CVID for the first time. These observations lead to a new perspective on the underlying genetic heterogeneity of CVID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
ORCID-Profile: Anli Liu
Förderung
- State Key Clinical Specialty of China for Hematological Diseases
- National Natural Science Foundation of China
- Rongxiang Regenerative Medicine Foundation of Shandong University
Zitieren
APA
Liu, A., Liu, Q., Leng, S., Zhang, X., Feng, Q., Peng, J., & Feng, G. (2023). Identification of novel NFKB1 and ICOS frameshift variants in patients with CVID. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxac121
Vancouver
Liu A, Liu Q, Leng S, Zhang X, Feng Q, Peng J, et al. Identification of novel NFKB1 and ICOS frameshift variants in patients with CVID. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxac121
BibTeX
@article{Liu2023,
author = {Liu, Anli and Liu, Qiang and Leng, Shaoqiu and Zhang, Xiaoyu and Feng, Qi and Peng, Jun and Feng, Gege},
title = {Identification of novel NFKB1 and ICOS frameshift variants in patients with CVID},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxac121}
}
EUVIMED